Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health
- Authors
- Park, Keun-Ho; Jeong, Myung Ho; Ahn, Youngkeun; Ahn, Tae Hoon; Seung, Ki Bae; Oh, Dong Joo; Choi, Dong-Joo; Kim, Hyo-Soo; Gwon, Hyeon Cheol; Seong, InWhan; Hwang, Kyung Kuk; Chae, Shung Chull; Kim, Kwon-Bae; Kim, Young Jo; Cha, Kwang Soo; Oh, Seok Kyu; Chae, Jei Keon
- Issue Date
- 15-7월-2016
- Publisher
- ELSEVIER IRELAND LTD
- Keywords
- Myocardial infarction; Ticagrelor; Hemorrhage; Far East
- Citation
- INTERNATIONAL JOURNAL OF CARDIOLOGY, v.215, pp.193 - 200
- Indexed
- SCIE
SCOPUS
- Journal Title
- INTERNATIONAL JOURNAL OF CARDIOLOGY
- Volume
- 215
- Start Page
- 193
- End Page
- 200
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/88063
- DOI
- 10.1016/j.ijcard.2016.04.044
- ISSN
- 0167-5273
- Abstract
- Background: Although ticagrelor has been well-known to improve clinical outcomes in patients with acute myocardial infarction (AMI) without increased bleeding risk, its clinical impacts have not been well established in East Asian patients. Methods: Between November 2011 and June 2015, a total of 8010 patients (1377 patients were prescribed ticagrelor and 6633 patients clopidogrel) undergoing successful revascularization were analyzed from Korea Acute Myocardial Infarction Registry-National Institute of Health. The patients who discontinued or occurred in-hospital switching between two antiplatelet agents were excluded. Results: After propensity score matching (1377 pairs), no difference in the composite of cardiac death, MI, stroke, or target vessel revascularization at 6 months was observed between two groups (4.2% vs. 4.9%, p = 0.499). However, the incidences of in-hospital Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding were higher in ticagrelor than clopidogrel (2.6% vs. 1.2%, p = 0.008; 3.8% vs. 2.5%, p = 0.051). The in-hospital mortality was higher in patients with than those without TIMI major bleeding (11.3% vs. 0.9%, p < 0.001). In a subgroup analysis, a higher risk for in-hospital TIMI major bleeding with ticagrelor was observed in patients = 75 years or with body weight < 60 kg (odd ratio [OR] = 3.209; 95% confidence interval [CI] = 1.356-7.592) and in those received trans-femoral intervention (OR = 1.996; 95% CI = 1.061-3.754). Conclusions: Our study shows that ticagrelor did not reduce ischemic events yet, however, was associated with increased risk of bleeding complications compared with clopidogrel. Further large-scale, long-term, randomized trials should be required to assess the outcomes of ticagrelor for East Asian patients with AMI. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.